Bleeding Risk in Hemodialysis Patients

Anita van Eck van der Sluijs; Pearl Pai; Wenjuan Zhu; Gurbey Ocak

doi:10.1016/j.semnephrol.2023.151478

Bleeding Risk in Hemodialysis Patients

Semin Nephrol. 2024 Jan 17:151478. doi: 10.1016/j.semnephrol.2023.151478. Online ahead of print.

Authors

Anita van Eck van der Sluijs¹, Pearl Pai², Wenjuan Zhu³, Gurbey Ocak⁴

Affiliations

¹ Department of Internal Medicine, Deventer Hospital, Deventer, The Netherlands. Electronic address: a.vaneckvandersluijs@dz.nl.
² Department of Medicine, University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong; Department of Medicine, University of Hong Kong Shenzhen Hospital, Shenzhen, China.
³ Department of Medicine, University of Hong Kong Shenzhen Hospital, Shenzhen, China.
⁴ Department of Internal Medicine, Sint Antonius Hospital, Nieuwegein, The Netherlands.

PMID: 38238225
DOI: 10.1016/j.semnephrol.2023.151478

Abstract

Cardiovascular diseases are highly prevalent among patients on dialysis. For these diseases, antiplatelets and antithrombotic therapies including heparin, vitamin K antagonists, and direct oral anticoagulants, are being used. However, the benefit-risk balance of these therapies could differ for dialysis patients compared with the general population. This review article focuses on the bleeding risk associated with the use of heparin, antiplatelets, vitamin K antagonists, and direct oral anticoagulants in patients receiving hemodialysis.

Keywords: Antiplatelets; bleeding; direct oral anticoagulants; hemodialysis; heparin; vitamin K antagonists.

Publication types

Review